A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

October 8, 2022

Study Completion Date

October 8, 2022

Conditions

Advanced Solid Tumors

Interventions

DRUG

YH001

YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .

Trial Locations (3)

Beijing Cancer Hospital, Beijing

Shanghai Pulmonary Hospital, Shanghai

West China Hospital,Sichuan University, Chengdu

All Listed Sponsors

lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY

NCT04699929 - A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter